Drug Profile

Research programme: T cell receptor cell therapies - Legend Biotech USA

Alternative Names: TCR-T cell therapies - Legend Biotech

Latest Information Update: 21 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Legend Biotech USA
Developer Noile-Immune Biotech
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Chemokine-CCL19-expression stimulants; Immunologic cytotoxicity; Interleukin 17 expression stimulants; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

18 Feb 2022 Legend Biotech USA terminates licensing agreement with Noile-Immune Biotech
28 Jan 2022 Discontinued for Solid tumours in USA (Parenteral)
08 May 2020 Research programme: T cell receptors T cell therapies is available for licensing as of 08 May 2020. https://www.legendbiotech.com/contact-us.php

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com